A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

被引：0
|
作者：
Fuchs, C. [1 ]
Shahidi, J. [2 ]
Mathew, L. [2 ]
Qin, A. [2 ]
Van Cutsem, E. [3 ,4 ]
机构：
[1] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA
[2] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[3] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-184
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 50 条
  • [21] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
    Smit, Egbert F.
    Nakagawa, Kazuhiko
    Nagasaka, Misako
    Felip, Enriqueta
    Goto, Yasushi
    Li, Bob T.
    Pacheco, Jose Maria
    Murakami, Haruyasu
    Barlesi, Fabrice
    Saltos, Andreas Nicholas
    Perol, Maurice
    Udagawa, Hibiki
    Saxena, Kapil
    Shiga, Ryota
    Guevara, Ferdinand M.
    Acharyya, Suddhasatta
    Shahidi, Javad
    Planchard, David
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
    Geyer, Charles E., Jr.
    Untch, Michael
    Prat, Aleix
    Rastogi, Priya
    Niikura, Naoki
    Mathias, Elton
    McLean, Lee Anne
    Wang, Yibin
    Loibl, Sibylle
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
    Geyer, Charles E., Jr.
    Untch, Michael
    Prat, Aleix
    Rastogi, Priya
    Niikura, Naoki
    Mathias, Elton
    McLean, Lee Anne
    Wang, Yibin
    Loibl, Sibylle
    CANCER RESEARCH, 2022, 82 (04)
  • [25] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)
    Cortes, Javier
    Shahidi, Javad
    Lee, Caleb
    Zhang, Yufen
    Verma, Sunil
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Janjigian, Y.
    Rha, S.
    Oh, D.
    Diez Garcia, M.
    van Laarhoven, H.
    Chao, Y.
    Di Bartolomeo, M.
    Mohammad, N. Haj
    Zhong, W.
    Croydon, E.
    Cecchi, F.
    Lee, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S358 - S359
  • [27] Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Andre, Fabrice
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Yu, Tinghui
    Lu, Shiyao
    Boston, Sarice
    D'Cruz, Celina
    Herbolsheimer, Pia
    Jhaveri, Komal
    CANCER RESEARCH, 2021, 81 (04)
  • [28] A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
    Janjigian, Y. Y.
    Lloyd, C.
    de Giorgio-Miller, V. G.
    Chang, Y-T.
    Lee, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1502 - S1503
  • [29] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345